Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier Gene Therapy For Retinitis Pigmentosa, In The Middle East And North Africa

Benzinga Newsdesk www.benzinga.com Positive 63.8%

Neg 0% Neu 0% Pos 63.8%

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones
Royalties equaling 22% of net sales
Ocugen to manufacture and supply OCU400

Comments

No comments yet. Be the first!